FAQ: Oncotelic Therapeutics Inc. (OTLC) and Its Innovations in Biopharmaceuticals

What is Oncotelic Therapeutics Inc. (OTLC) and what does it focus on?

Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company developing RNA-based, immunotherapy, and targeted therapeutics for cancer and other underserved diseases, with a focus on transforming outcomes for patients with difficult-to-treat and rare conditions, particularly pediatric cancers and aggressive solid tumors.

What is the lead candidate of Oncotelic Therapeutics and what is its current status?

The company’s lead candidate, OT-101, is currently in a Phase 3 trial for pancreatic cancer and is advancing toward combination studies with checkpoint inhibitors.

How does Oncotelic Therapeutics accelerate its research and development processes?

Oncotelic accelerates development through a joint venture with GMP Biotechnology for low-cost R&D and in-house GMP manufacturing, and a strategic partnership with Shanghai Medicilon supporting rapid IND filings for up to 20 drug candidates, significantly accelerating timelines.

What proprietary technology does Oncotelic Therapeutics use to enhance its workflows?

Oncotelic’s proprietary AI platform, PDAOAI, enhances regulatory and research workflows while offering public engagement tools for added transparency.

What are the key disease areas covered by Oncotelic Therapeutics’ pipeline?

The company maintains a multi-indication pipeline spanning oncology, Parkinson’s disease, erectile dysfunction, and female sexual dysfunction, providing broad commercialization potentials.

Who is the Chairman and CEO of Oncotelic Therapeutics and what is his background?

Chairman and CEO Dr. Vuong Trieu is a prolific industry pioneer who has filed more than 500 patents with 75 issued patents across biologics, small molecules, nanoparticles, and diagnostics, and co-invented Abraxane® (sold to Celgene for $2.9 billion).

Where can I find the latest news and updates about Oncotelic Therapeutics?

The latest news and updates relating to OTLC are available in the company’s newsroom at https://ibn.fm/OTLC.

What is the significance of recent peer-reviewed publications for Oncotelic Therapeutics?

Recent peer-reviewed publications support OT-101’s mechanism of action and spotlight TGF-β2 as a survival-linked biomarker in younger PDAC patients, validating the scientific basis of their lead candidate.